HIGHLIGHTS
- who: S Betrian from the (UNIVERSITY) have published the article: Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment, in the Journal: (JOURNAL)
- what: The authors assessed the efficacy of BI 836826 on global and chemoresistant SP B-cell depletion from relapsed CLL patient`s samples ex vivo (Supplementary Information 1).
- how: The authors collected samples from relapsed patients mainly after FR/FCR treatment and from a phase I clinical study with BI 836826 monotherapy for CLL patients.
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.